Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma

NCT07581509 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)

Interventions

BIOLOGICAL: Bmab1800
BIOLOGICAL: US-Licensed Keytruda

Sponsor

Biocon Biologics UK PLC